OALib Journal期刊
Pilot study of bevacizumab in combination with docetaxel and
cyclophosphamide as adjuvant treatment for patients with early stage HER-2
negative breast cancer, including analysis of candidate circulating markers of
cardiac toxicity: ICORG 08–10 trial
DOI: 10.1177/1758835919864236
Alex J. Eustace ,
Alexandra Canonici ,
Alice C. O’Farrell ,
Andres Hernando ,
Annette T. Byrne ,
Ashwini Maratha ,
Bonnie Ky ,
Brian Moulton ,
David W. Murray ,
Denis M. Collins ,
Dimitrios Tryfonopoulos ,
Enda McDermott ,
Giuseppe Gullo ,
Gregory Leonard ,
Imelda Parker ,
Janice Walshe ,
John Crown ,
John McCaffrey ,
Kathleen Scott ,
Liam Grogan ,
Maccon Keane ,
Mairin Rafferty ,
Michael J. Kennedy ,
Michael J. Martin ,
Miriam O’Connor ,
Norma O’Donovan ,
Oscar Breathhnach ,
Patrick Dicker ,
Paul Donnellan ,
Paula M. Calvert ,
Rajnish Gupta ,
Verena Murphy ,
William M. Gallagher Keywords: bevacizumab , breast cancer , cardiotoxicity biomarker , docetaxel/cyclophosphamide
Abstract:
Full-Text
Please enable JavaScript to view the comments powered by Disqus.
comments powered by
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
